RLMD Stock Analysis: Buy, Sell, or Hold?
RLMD - Relmada Therapeutics, Inc. Common Stock
$3.83
0.28 (7.89%)
▲
5d:
-3.53%
30d:
-20.7%
90d:
+65.09%
BUY
MODERATE Confidence
Last Updated: February 2, 2026
Earnings: Mar 26, 2026
Smart Money Accumulation
RLMD is down 9.0% this week, but smart money is accumulating calls. Top strike: $5 2026-03-20 with 8 OI. Call ratio: 100% View Scanner →
Strength: 9.5/10
Get Alerted When RLMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RLMD shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: RLMD shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: RLMD is currently trading at $3.83, which is considered slightly low relative to its 30-day fair value range of $3.80 to $4.40.
Technical Outlook: Technically, RLMD is in a strong uptrend. Immediate support is located at $3.51, while resistance sits at $4.53. The stock is showing strong short-term momentum, up 7.9% recently.
Market Sentiment: RLMD has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $5.50 (+43.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RLMD is in a strong uptrend. Immediate support is located at $3.51, while resistance sits at $4.53. The stock is showing strong short-term momentum, up 7.9% recently.
Market Sentiment: RLMD has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $5.50 (+43.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$3.80 -
$4.40
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.9%)
- BULLISH: Trading 43.6% below Wall St target ($5.50)
Fair Price Analysis
30-Day Fair Range
$3.80 -
$4.40
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$3.51
Resistance Level
$4.53
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-10.64
Wall Street Target
$5.50
(+43.6%)
Last updated: February 03, 2026 6:52 AM ET
Data refreshes hourly during market hours. Next update: 7:52 AM
Data refreshes hourly during market hours. Next update: 7:52 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RLMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$213 | 61 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$56 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 57 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 60 HOLD |
|
ARVN
Arvinas Inc |
BUY
21 analysts |
$13 | 58 HOLD |
